Reported about 3 hours ago
Roche has agreed to acquire the U.S. biotech firm 89bio for up to $3.5 billion to enhance its pipeline for treating liver and cardiometabolic diseases, particularly in the growing weight-loss market. The deal includes a purchase of all common shares at $14.50 each and potential milestone payments. This acquisition reflects Roche's commitment to developing therapies for conditions like fatty liver and obesity.
Source: YAHOO